Companion Animal Anthelmintics Market Size, Share, Growth, and Industry Analysis, By Types (External Use, Internal Use), By Applications Covered (Dogs, Cats, Birds, Other), Regional Insights and Forecast to 2033

Companion Animal Anthelmintics Market Size

The Companion Animal Anthelmintics Market size was USD 69.84 Million in 2024 and is projected to touch USD 72.01 Million in 2025 to USD 92.02 Million by 2033, exhibiting a CAGR of 3.11% during the forecast period [2025-2033]. This consistent growth highlights rising global pet care awareness, increasing adoption of combination therapies, and expanded online retail presence, enhancing market reach across North America, Europe, and Asia-Pacific, making preventive deworming treatments more accessible and effective for pet owners worldwide.

The U.S. holds 36% of the global companion animal anthelmintics market share, driven by advanced veterinary infrastructure and high pet ownership. Routine deworming adoption has increased by 42%, supported by 35% growth in online product availability and 31% regulatory promotion of preventive treatments.

Key Findings

• Market Size: Valued at 72.01M in 2025, expected to reach 92.02M by 2033, growing at a CAGR of 3.11%.
• Growth Drivers: Routine veterinary recommendations increased by 42%, preventive care adoption rose by 37%, and combination therapies contributed 33% to new product innovations.
• Trends: Online sales expanded by 35%, palatable oral formulations covered 33% of new launches, and combination therapies reached 33% market share.
• Key Players: Boehringer Ingelheim, Zoetis, Merck, Elanco, Virbac.
• Regional Insights: North America holds 43% market share with advanced veterinary care. Europe follows with 29% supported by regulatory initiatives. Asia-Pacific accounts for 21% driven by rising pet ownership. The Middle East & Africa hold 7% supported by growing urbanization, completing the overall 100% market share distribution.
• Challenges: Drug resistance affects 29% of treatments, counterfeit products represent 12% of online sales, and side effects impact 17% of usage.
• Industry Impact: Veterinary partnerships cover 39% of clinic supplies, e-commerce channels contribute 35%, and telehealth services expand by 28% in product accessibility.
• Recent Developments: Combination therapies grew by 33%, regulatory approvals increased by 31%, e-commerce sales expanded by 35%, and veterinary telehealth consultations rose by 28%.

The companion animal anthelmintics market is expanding with increased pet ownership and rising awareness of parasitic control, contributing to over 32% growth in preventive treatments. Internal anthelmintics account for nearly 58% of total market demand, targeting gastrointestinal worms effectively. Dogs represent the dominant application segment with nearly 61% market share due to their higher exposure to outdoor environments. Oral administration methods lead with approximately 67% preference among pet owners for convenience. North America holds around 43% of the global share, followed by Europe at 29% and Asia-Pacific at 21%, driven by increasing pet care expenditure.

Companion Animal Anthelmintics Market Trends

The market for companion animal anthelmintics is increasingly driven by demand for broad-spectrum treatments, accounting for approximately 49% of product sales. Preventive care adoption has grown by over 37% among pet owners, reflecting increased awareness of zoonotic diseases. Internal deworming treatments lead with a 58% share, with oral solutions preferred in 67% of applications due to ease of use. Dogs account for 61% of product usage, followed by cats at 28%, and other companion animals at 11%. North America maintains a 43% market share, supported by veterinary infrastructure. Europe follows with 29%, while Asia-Pacific records 21% growth. Online distribution channels have expanded by 35%, improving product accessibility. Regulatory support for preventive treatments has influenced nearly 41% of veterinary recommendations. Combination therapies addressing multiple parasites now account for 33% of newly introduced products. Veterinary partnerships with pharmaceutical brands cover 39% of clinic supplies, enhancing market reach. Pet humanization trends are boosting routine deworming adoption by 42%, ensuring sustained market expansion in the coming years.

Companion Animal Anthelmintics Market Dynamics

OPPORTUNITY

Expansion Through E-commerce and Combination Therapies

Online retail growth contributes to 35% of market accessibility, creating new sales channels for anthelmintic products. Combination therapies addressing both internal and external parasites account for 33% of new product launches, offering a comprehensive solution for pet owners. Veterinary telehealth services have grown by 28%, providing remote consultation and increasing treatment adoption. Premiumization trends influence 47% of consumers to seek advanced formulations with fewer side effects. Pet care campaigns boost awareness by 31%, driving higher participation in routine deworming. Increased pet insurance coverage, now reaching 22% of pet owners, supports market growth by covering preventive treatments.

DRIVERS

Rising Demand for Preventive Pet Health Solutions

Increasing awareness among pet owners has led to a 42% rise in preventive deworming treatments across veterinary clinics. The growing dog population accounts for nearly 61% of the market demand, as dogs are highly vulnerable to internal and external parasites. Regulatory promotion of regular deworming practices supports over 39% of veterinary recommendations. Online sales channels contribute to 35% of the product distribution, expanding consumer reach. Innovations in palatable oral formulations cover nearly 33% of newly introduced products, encouraging higher compliance. Pet humanization trends influence 47% of owners to invest in premium anthelmintic solutions, driving market expansion globally.

RESTRAINT

"Growing Concerns Over Drug Resistance and Side Effects"

Drug resistance is reported in approximately 29% of veterinary cases, posing a major restraint on market expansion. Adverse side effects, including gastrointestinal discomfort, affect nearly 17% of treated animals, reducing product acceptance. The presence of counterfeit products in the market represents 12% of online sales, raising concerns over product efficacy and safety. Limited awareness in developing regions accounts for 23% of missed deworming opportunities. Cost sensitivity among pet owners in low-income regions impacts 26% of potential sales. Veterinary professionals report that 19% of pet owners skip deworming due to lack of knowledge on parasite risks, slowing market penetration.

CHALLENGE

"Regulatory Hurdles and Distribution Limitations in Developing Markets"

Regulatory complexities impact 24% of product approvals, delaying market entry for new anthelmintic formulations. Supply chain disruptions in emerging markets affect 19% of product availability, limiting access for rural veterinary practices. Limited veterinary infrastructure in underdeveloped regions influences 21% of untapped market potential. Product pricing remains a challenge for 26% of consumers in cost-sensitive regions. Additionally, 12% of counterfeit product circulation undermines brand trust and poses safety risks. Resistance management protocols are implemented in only 34% of clinics, highlighting gaps in veterinary practices. These challenges collectively restrict consistent market penetration across various geographical regions.

Segmentation Analysis

The companion animal anthelmintics market is segmented by type and application. Internal use treatments dominate with 58% market share, focusing on gastrointestinal parasite control through oral and injectable formulations. External use products cover 42%, targeting fleas, ticks, and mites through topical solutions. By application, dogs lead with 61% of the market, followed by cats at 28%, birds at 7%, and other small pets at 4%. Product innovation focuses on palatable formulations covering 33% of new launches. Routine veterinary care adoption influences 42% of deworming treatments, ensuring continuous demand across various pet species globally.

By Type

• External Use: External anthelmintic products, including sprays, spot-on treatments, and collars, represent 42% of total product usage. These are highly effective against fleas, ticks, and mites, covering approximately 37% of ectoparasite control cases. Pet owners prefer external use solutions for ease of application, accounting for 33% of repeat purchases. Dogs and cats make up 87% of users for these products, driven by increasing outdoor activities. Topical solutions reduce parasite transmission risks by 29%, promoting preventive care practices. Veterinary professionals recommend external treatments in nearly 31% of pet check-ups to complement internal deworming.
• Internal Use: Internal use anthelmintics dominate the market with 58% share, focusing on treating gastrointestinal worms, heartworms, and tapeworms. Oral tablets, liquids, and injectables cover 67% of this segment’s product formats. Dogs lead the segment with 61% usage, followed by cats at 28%. Palatable oral formulations represent 33% of new product introductions, improving administration compliance. Preventive internal treatments are recommended in 39% of veterinary visits to manage parasite control. Combination therapies addressing both internal and external parasites make up 33% of internal use product innovations, enhancing treatment efficiency for pet owners.

By Application

• Dogs: Dogs hold the largest market share with 61%, making them the primary application segment. Outdoor exposure and higher risk of parasitic infections drive 42% of routine deworming treatments for dogs. Oral formulations are preferred in 67% of dog deworming cases. Veterinary clinics recommend deworming for dogs in 39% of check-ups. Preventive care adoption for dogs has increased by 47%, reflecting growing pet humanization trends. Dogs account for 33% of combination therapy usage to target internal and external parasites.
• Cats: Cats contribute 28% to the overall market, driven by rising indoor pet ownership. Routine deworming for cats is recommended in 31% of veterinary visits. Oral and topical formulations cover 58% of cat treatments. Preventive care adoption among cat owners has grown by 37%, reflecting increased awareness of zoonotic disease risks. Combination therapies account for 29% of treatments in cats, ensuring comprehensive parasite control.
• Birds: Birds represent 7% of the market, requiring specialized formulations. Deworming treatments for birds cover 25% of avian veterinary consultations. Internal parasite control products account for 61% of bird-specific treatments. Preventive care adoption among bird owners has grown by 22%, promoting regular parasite management. Combination therapies make up 19% of bird anthelmintic solutions.
• Other Companion Animals: Other companion animals, including rabbits and small mammals, hold a 4% market share. Veterinary recommendations for these animals account for 17% of niche pet healthcare services. Internal parasite treatments cover 53% of product usage in this segment. Preventive care practices have grown by 19%, reflecting increased awareness among niche pet owners. Combination therapies account for 12% of treatments in other companion animals.

Regional Outlook

The companion animal anthelmintics market shows strong growth across North America, Europe, Asia-Pacific, and the Middle East & Africa. North America leads with a 43% share, supported by advanced veterinary care and high pet healthcare spending. Europe follows with 29%, driven by strong regulatory frameworks promoting preventive care. Asia-Pacific records 21% growth, supported by increasing pet adoption and awareness campaigns. The Middle East & Africa, though holding a smaller 7% share, shows potential due to rising urbanization and pet ownership trends. E-commerce expansion and veterinary partnerships are improving market reach across all these regions.

North America

North America dominates the market with 43% of the global share, led by the United States, which accounts for 36% of the regional demand. The region benefits from advanced veterinary healthcare infrastructure and pet insurance coverage reaching 22% of pet owners. Preventive care awareness has grown by 37%, boosting routine deworming adoption. Online retail channels contribute to 35% of product sales, improving consumer access. Dogs represent 61% of market demand, followed by cats at 28%. Veterinary clinics recommend deworming in 39% of check-ups, highlighting strong adherence to parasite control protocols in North America.

Europe

Europe holds a 29% market share, with Germany, France, and the United Kingdom leading in product demand. Pet healthcare expenditure has increased by 31%, supporting higher sales of preventive treatments. Regulatory initiatives promote routine deworming in nearly 41% of veterinary consultations. Dogs make up 59% of the regional demand, followed by cats at 30%. Online distribution channels have expanded by 28%, improving product availability. Combination therapies represent 33% of new product introductions in Europe, addressing multi-parasite infections. Veterinary partnerships with pharmaceutical brands cover 39% of clinic supplies, ensuring efficient product distribution across the region.

Asia-Pacific

Asia-Pacific records 21% market growth, with China, Japan, and Australia leading in pet healthcare investments. Pet ownership has increased by 34%, boosting demand for anthelmintic products. Dogs account for 62% of market usage, followed by cats at 27%. Veterinary infrastructure development has improved by 29%, supporting higher treatment adoption. Online sales channels have grown by 32%, enhancing consumer reach. Preventive care campaigns have raised awareness by 31%, encouraging routine deworming practices. Combination therapies make up 33% of product launches, catering to regional needs for comprehensive parasite control in companion animals.

Middle East & Africa

The Middle East & Africa hold a 7% share of the global market, with South Africa and the United Arab Emirates as key contributors. Pet ownership in urban areas has grown by 26%, driving demand for anthelmintic products. Veterinary services have expanded by 22%, improving access to preventive treatments. Dogs account for 58% of product usage, followed by cats at 30%. Awareness campaigns have increased by 29%, promoting routine deworming practices. E-commerce platforms have grown by 25%, supporting product accessibility. Veterinary partnerships cover 33% of clinic supplies, ensuring steady market development across the region.

List Of Key Company Profiles

Investment Analysis and Opportunities

Investments in the companion animal anthelmintics market are rising, with pharmaceutical companies increasing research and development spending by 34% to introduce advanced products. Veterinary partnerships now cover 39% of clinic supplies, improving product accessibility. Online retail platforms have expanded by 35%, creating new revenue streams for manufacturers. Emerging markets in Asia-Pacific and the Middle East & Africa show 29% growth potential, driven by rising pet ownership and urbanization. Regulatory approvals for combination therapies have increased by 33%, supporting multi-parasite treatment solutions. Preventive care initiatives backed by government campaigns have improved awareness by 31%, encouraging routine deworming adoption. Veterinary telehealth services have grown by 28%, providing remote consultation options and expanding market reach. Pet insurance coverage has risen by 22%, supporting consumer spending on preventive treatments. Innovations in palatable formulations cover 33% of new product launches, improving compliance among pet owners. Combination therapies now represent 33% of the market, addressing both internal and external parasites. Veterinary recommendations for routine deworming have increased by 42%, driving higher product uptake. North America leads investments with a 43% share, followed by Europe at 29% and Asia-Pacific at 21%. Strategic collaborations and e-commerce expansion continue to create growth opportunities in the global market.

New Products Development

New product development in the companion animal anthelmintics market focuses on creating effective and easy-to-administer solutions. Combination therapies addressing multiple parasites account for 33% of newly introduced products, offering comprehensive protection. Palatable oral formulations have grown by 33%, improving pet compliance and reducing treatment refusals. External use products, including spot-on treatments and collars, represent 42% of new developments, targeting fleas, ticks, and mites. Injectable solutions for gastrointestinal parasites now cover 27% of product innovations, improving veterinary-administered treatments. Veterinary clinics report a 39% increase in stocking newly launched products to meet growing pet owner demand. E-commerce platforms have expanded their offerings by 35%, ensuring wider accessibility of new products. Regulatory approvals for new formulations have increased by 31%, accelerating market entry. Pet humanization trends influence 47% of product development strategies, focusing on safety and minimal side effects. Veterinary professionals recommend new products in 42% of consultations, reflecting trust in advanced solutions. North America leads new product adoption with a 43% share, followed by Europe at 29% and Asia-Pacific at 21%. Strategic R&D investments have increased by 34%, supporting continuous innovation and addressing evolving parasite resistance challenges in companion animal healthcare.

Recent Developments 

• Zoetis launched a new palatable oral combination therapy in 2023, covering internal and external parasites, representing 33% of its product innovation pipeline.
• Boehringer Ingelheim introduced a fast-acting injectable solution for heartworm prevention in 2024, expanding its internal use portfolio by 27%.
• Elanco expanded its online retail partnerships in 2023, increasing e-commerce sales by 35% to improve consumer access to its anthelmintic products.
• Virbac gained regulatory approval in 2024 for a multi-parasite treatment targeting dogs and cats, contributing to a 31% increase in veterinary clinic recommendations.
• Merck Animal Health partnered with veterinary telehealth providers in 2023, boosting remote treatment consultations by 28% and expanding market reach.

Report Coverage 

The companion animal anthelmintics market report provides comprehensive coverage of key segments, including type, application, and regional analysis. Internal use products dominate with 58% market share, targeting gastrointestinal and heartworm infections. External use solutions represent 42%, focusing on fleas, ticks, and mites. Dogs lead the application segment with 61%, followed by cats at 28%, birds at 7%, and other small pets at 4%. North America holds the largest regional share at 43%, followed by Europe at 29% and Asia-Pacific at 21%. Market drivers include a 42% increase in routine veterinary deworming recommendations and 33% growth in combination therapy adoption. Challenges include 29% of cases reporting drug resistance and 17% experiencing treatment side effects. Online sales channels contribute to 35% of product distribution, improving market reach. Veterinary partnerships cover 39% of clinic supplies, ensuring product availability. New product innovations focus on palatable formulations, covering 33% of launches. Regulatory approvals have increased by 31%, supporting faster market expansion. The report highlights investment opportunities in emerging markets, driven by 29% growth potential. Strategic collaborations, e-commerce expansion, and preventive care campaigns continue to shape the future of the companion animal anthelmintics market.